N/A N=20 Nasotracheal Suction With Tiemann Catheter Compared to the Classic Technique With the Suction Catheter
Muscle Weakness
Primary: Number of Attempts Before Entering Trachea — 2.63; 6.79 Attempts — p=<0.05
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
N/A N=1,024 An Evaluation of a Web-based Intervention Program for Parents and Teens to Promote Safe Driving
Novice Teen Driver Training
Primary: Late Driving Performance in On-road Assessment (ODA) Test — 5; 10 Participants
N/A N=35 Pharmacodynamic Effects of Dabigatran in Patients on Dual Antiplatelet Therapy
Coronary Artery Disease
Primary: TRAP-induced Platelet Aggregation — 74; 77 percentage of aggregation — p=<0.05
N/A N=52 Effects of Training on Central Auditory Function in Multiple Sclerosis
Multiple Sclerosis
Primary: Electrophysiological Auditory Test — 13.1; 6.4; 6.6 microvolts
Phase 2 N=23 Activity of Valomaciclovir in Infectious Mononucleosis Due to Primary Epstein-Barr Virus Infection
Infectious Mononucleosis
Primary: Number of Participants With Improvement in Clinical Symptoms and Reductions in Viral Burden From Baseline — 12; 11 participants
N/A N=1,049 LIpid Lowering With Highly Potent Statins in Hyperlipidaemia With Type 2 Diabetes patiENts
Hypercholesterolemia With Concomitant Type 2 Diabetes
Primary: Percent Change in Non-high-density Lipoprotein Cholesterol (HDL-C) Level — -31.3; -32.8 Percent change
N/A N=59 Ischemia/Reperfusion Injury of Human Endothelium: Role of Glucose and Statins
Hyperglycemia
Primary: Forearm Blood Flow — 6.48; 9.2; 7.32; 8.26 ml/100 ml tissue/min
N/A N=108 Pruritus in Patients With Chronic Kidney Disease
Kidney Failure, Chronic · Pruritus
Primary: Visual Analog Scale (VAS) — 3.35 units on a scale
Phase 2 N=78 DHA and X-Linked Retinitis Pigmentosa
Retinitis Pigmentosa · X-linked Genetic Diseases
Primary: Rate of LOSS of 31 Hertz Cone Electroretinographic Function — 0.028; 0.022 log microvolts/year — p=0.30
Phase 3 N=1,101 Evaluation of a New Cardiac Biomarker Assay
Acute Coronary Syndrome · Acute Myocardial Infarction
Primary: Clinical Performance - Area Under the Curve — 0.9326; 0.9197; 0.9412; 0.9431 Probability
Phase 4 N=228 Safety and Efficacy Study to Compare Vildagliptin to Pioglitazone as Adding on Metformin in Type 2 Diabetes
Type 2 Diabetes
Primary: Non-inferiority of HbA1C Change From Baseline in Vildagliptin + Metformin Group Compared With Pioglitazone + Metformin Group — -0.94; -0.60 % (change of HbA1c)
Phase 4 N=43 Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function
Type 2 Diabetes · Healthy · Impaired Glucose Tolerance
Primary: Effect of Pioglitazone, Exenatide and Combined Pioglitazone and Exenatide on Body Weight — 5.5; 2.4; 2.7 kg — p=<0.05
Phase 2 N=26 Post-transplant Cyclophosphamide and Sirolimus Following Reduced Intensity Conditioning (RIC) Transplant
Hematologic Neoplasms
Primary: Incidence of GVHD — 12 participants
Phase 3 N=304 VEGF Trap-Eye: Investigation of Efficacy and Safety in Chinese Subjects With Wet AMD (Age-Related Macular Degeneration)
Macular Degeneration
Primary: Change From Baseline in Best Corrected Visual Acuity (BCVA) as Measured by ETDRS Letter Score at Week 28 - Last Observation Carried Forward (LOCF) — 14.0; 3.9 Letters…
Phase 2 N=111 Safety and Efficacy of PCI-32765 in Participants With Relapsed/Refractory Mantle Cell Lymphoma (MCL)
Mantle Cell Lymphoma
Primary: Percentage of Participants Achieving Response — 67.6 percentage of participants with response